A multicenter, open-label trial to evaluate the effects of zoledronic acid on circulating tumor cells in patients with castration resistant prostate cancer (CRPC) with bone metastasis.

Trial Profile

A multicenter, open-label trial to evaluate the effects of zoledronic acid on circulating tumor cells in patients with castration resistant prostate cancer (CRPC) with bone metastasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms CRPC with BM/ZOL-CTC
  • Most Recent Events

    • 26 May 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 15 Jan 2014 Planned End Date changed from 1 Dec 2013 to 31 Mar 2014, as reported by University Hospital Medical Information Network - Japan.
    • 15 Jan 2014 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top